Leerink Partnrs Has Positive Estimate for RXRX Q2 Earnings

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Research analysts at Leerink Partnrs lifted their Q2 2025 earnings estimates for Recursion Pharmaceuticals in a report issued on Tuesday, May 6th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($0.34) for the quarter, up from their prior forecast of ($0.40). The consensus estimate for Recursion Pharmaceuticals' current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals' Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.92) EPS and FY2027 earnings at ($0.47) EPS.

RXRX has been the topic of several other reports. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Morgan Stanley dropped their price target on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Needham & Company LLC cut their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Finally, Leerink Partners decreased their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $7.60.

Recursion Pharmaceuticals Price Performance

Shares of RXRX traded down $0.10 during trading hours on Thursday, hitting $4.54. The stock had a trading volume of 12,649,289 shares, compared to its average volume of 12,980,325. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -2.97 and a beta of 0.99. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company's fifty day moving average is $5.49 and its two-hundred day moving average is $6.65. Recursion Pharmaceuticals has a 52 week low of $3.79 and a 52 week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. During the same period in the prior year, the firm earned ($0.39) EPS. Recursion Pharmaceuticals's quarterly revenue was up 7.2% compared to the same quarter last year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Large investors have recently made changes to their positions in the company. Barclays PLC lifted its position in Recursion Pharmaceuticals by 53.9% during the 3rd quarter. Barclays PLC now owns 697,432 shares of the company's stock valued at $4,596,000 after purchasing an additional 244,278 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Recursion Pharmaceuticals by 6.1% during the third quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company's stock worth $7,751,000 after buying an additional 67,464 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after buying an additional 4,948 shares during the period. Green Alpha Advisors LLC grew its holdings in Recursion Pharmaceuticals by 3.6% during the 4th quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company's stock worth $454,000 after acquiring an additional 2,346 shares during the period. Finally, DBK Financial Counsel LLC bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at $101,000. Institutional investors and hedge funds own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.